EWTX: Edgewise Therapeutics, Inc.
Performance
EWTX +184.03%
Watchlist
Select an item
Summary
EWTX at a glance
EWTX returned +184.03% over the past year and +19.56% a year over five years. Its worst drop in that year was -24.96%, smaller than 69% of stocks on Redstone, and its Sharpe ratio of 1.71 beats 95% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
70.85%
Actions
Metrics
Risk Indicators
Alpha116.59%
Beta1.18x
Sharpe1.71
Sortino3.28
Omega1.39
Calmar7.37
Martin11.70
Profile
About EWTX
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $5.3B
- Listed
- Mar 2021
- Employees
- 127
- Headquarters
- Boulder, CO
- Website
- edgewisetx.com
Comparisons